KPV

What the Colitis Models Reported

UKPWritten and published by UK Peptides2 min readUpdated 2 cited sources

The short answer

Kannengiesser and colleagues reported that the melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine colitis models, published in Inflammatory Bowel Disease in 2008. It is a mouse disease model, and the distance from there to a clinical claim is substantial.

Key facts

Publication
Inflamm Bowel Dis, March 2008
PMID
18092346
Model organism
Mouse
Model type
Induced colitis
Reported
Anti-inflammatory potential
Human trials
None established

Why colitis models are used

Induced colitis in mice is a standard model for intestinal inflammation, producing measurable tissue damage and inflammatory marker changes on a workable timescale. It is a well-established system with objective endpoints, which makes it a reasonable place to test an anti-inflammatory hypothesis.

What the study reported

Anti-inflammatory potential for KPV in that model. The paper's own language (potential) should be preserved, because it is more careful than the language that usually gets applied to it downstream. A compound showing an effect in an induced disease model has demonstrated something in that model.

Research material referenced

KPV 10mg, third-party HPLC tested

Buy KPV · £28.99

The gap between a model and a condition

Induced colitis in a mouse is not inflammatory bowel disease in a person. The induction is chemical and acute; human IBD is chronic, immunologically complex and heterogeneous. Model systems are chosen because they are tractable, and tractability is bought by simplifying away much of what makes the human condition difficult.

Why the gut was a natural target

Beyond the disease relevance, the intestine is where an orally administered compound would first arrive. The later delivery work, targeting KPV to inflamed intestinal tissue with hyaluronic acid-functionalised carriers, follows directly from this line, and indicates the difficulty was getting enough compound to the right place rather than the compound lacking activity.

What is not claimed

Nothing about inflammatory bowel disease, inflammation or gut health in any person. There is no established human clinical programme for KPV, it holds no marketing authorisation, and material supplied for laboratory research is not related to any therapeutic use.

Frequently asked questions

Has KPV been tested in humans?

No established clinical programme exists. The literature is cell culture and murine models.

Does the colitis result mean it treats IBD?

No. Induced colitis in a mouse is an acute chemical model; human inflammatory bowel disease is chronic and immunologically complex.

Why was the gut studied specifically?

It is both a disease-relevant tissue and where an orally administered compound would first arrive, which is why the later delivery work targets it.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More KPV articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.